Lilly has received FDA approval for a new norepinephrine reuptake inhibitor. Looking at the pharmacology, this medication is similar to the antidepressant effexor. But Lilly has done some research to justify the indication for ADD/ADHD.
This is significant because it's the first nonstimulant to be approved for ADD/ADHD.
And it's the first medication indicated for treating ADHD in adults.